TABLE 2.
Patient | Type of carea | Day of hospitalization post–symptom onset | Day of ICU transfer post–symptom onset | Type of O2 therapyb | Immuno suppression at onsetc | Immuno suppression level at diagnosisd | Immuno suppression taperinge | Immuno suppressants during COVID–19f | Day of immunosuppressive regimen resumptiong | Time of recovery post–symptom onset (days) | Sampling days post–symptom onseth |
---|---|---|---|---|---|---|---|---|---|---|---|
Kidney transplanted patients | |||||||||||
KTX1 | ICU | 4 | 5 | HFNC | Tac, MPA, Cs | Tac <2.2i MPA 500 mg x2 |
Tac↕, MPA↕ | Tac <2.2 Cs 20 mg |
24 (Tac MPA Cs 7.5 mg) | 24 | 19E–38S–60E,S |
KTX2 | ICU | 10 | 16 | HFNC | Tac, MPA, Cs | Tac 8 MPA 750 mg x2 |
Tac↕, MPA↕ | dy 13 Tac 4.4 dy 16 Tac<2.2 Cs 20 mg |
37 (Tac MPA Cs 10 mg) | 37 | 31E–53E,S |
KTX3 | ICU | 10 | 10 | MV | Bel, MPA, Cs | Bel day –27 MPA 500 mg x2 |
Bel↕, MPA↕ | Cs 20 mg | - (Cs 20 mg) | >80j | 26E,S |
KTX4 | Hosp | 7 | — | Conv | Tac, MPA, Cs | Tac 4.7 MPA 750 mg x 2 |
MPA↕ | Tac 4 Cs 20 mg |
12 (Tac MPA Cs 7.5 mg) | 12 | 42E,S |
KTX5 | ICU | 14 | 14 | HFNC | Tac, MPA, Cs | Tac 6.1 MPA 500 mg x2 |
MPA↕ | Tac 4 Cs 20 mg |
40 (Tac MPA Cs 7.5 mg) | 40 | 39E,S–56E,S |
KTX6 | Hosp | 12 | — | Conv | CsA, MPA | CsA 78 MPA 500 mg x 2 |
Csa↕, MPA↕ | Cs 20 mg | 25 (CsA MPA Cs 5 mg) | 29 | 26E,S |
KTX7 | Outpatient | — | — | — | Tac, MPA, Cs | Tac 6.6 MPA 500 mg x2 |
— | — | — | — | 48E,S |
KTX8 | Outpatient | — | — | — | Bel, MPA, Cs | Bel day 0 MPA 500 mg x2 |
— | — | — | — | 37E,S |
KTX9 | Outpatient | — | — | — | Bel, MPA, Cs | Bel day –5 MPA 500 mg x2 |
— | — | — | — | 37E,S |
KTX10 | Outpatient | — | — | — | Tac, MPA | Tac 9 MPA 750 mg x2 |
— | — | — | — | 40E,S |
KTX11 | Outpatient | — | — | — | Sir, Cs | Sir 10 | — | — | — | — | 49E,S |
Patients on hemodialysis | |||||||||||
HD1 | Outpatient | — | — | — | — | — | – | — | — | — | 21E,S–49S |
HD2 | Hosp | 4 | — | Conv | — | — | – | — | — | 16 | 17E |
ICU: intensive care unit; Hosp: patient hospitalized in conventional medical unit.
Conv: conventional oxygen therapy; HFNC: high-flow nasal canula; MV: mechanical ventilation.
Tac: tacrolimus; CsA: cyclosporine A; MPA: mycophenolic acid or mycophenolate mofetil; Cs: corticosteroids; Bel: belatacept. Sir: sirolimus.
Trough levels of tacrolimus (Tac), cyclosporine A (CsA), or sirolimus (Sir) in ng/ml, day of the last belatacept (Bel) infusion relative to symptoms onset, and mycophenolic acid or mycophenolate mofetil (MPA) dosage per day.
↕: withdrawal.
Trough levels of tacrolimus on the indicated day relative to symptoms onset and dosage of corticosteroids (Cs).
Immunosuppressive regimen at resumption in brackets. Immunosuppressants were not re-administered in patient KTX3.
The type of immunological assay performed at each sampling date is indicated as E: ELISPOT, S: serology. In bold, sampling done under or after reintroduction of a full immunosuppressive regimen.
Low Tac trough levels maintained prior to and after COVID-19 due to Kaposi sarcoma in this patient.
Patient still hospitalized in ICU due to post-COVID-19 pulmonary function impairment.